Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer
CompletedOBSERVATIONAL
Enrollment
89
Participants
Timeline
Start Date
February 29, 2004
Primary Completion Date
April 30, 2006
Study Completion Date
November 30, 2014
Conditions
Breast CancerAdenocarcinoma of Breast
All Listed Sponsors
lead
Hellenic Cooperative Oncology Group
OTHER
NCT04829890 - Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer | Biotech Hunter | Biotech Hunter